Comparison of non-invasive scores predictive of development of metabolic dysfunction associated liver disease in patients of type 2 diabetes mellitus and evaluation of additive effect of smoking in these patients
DOI:
https://doi.org/10.18203/2320-6012.ijrms20240665Keywords:
Type 2 diabetes mellitus, Smoking, Metabolic dysfunction associated liver disease, FIB-4 scoreAbstract
Background: Metabolic dysfunction associated liver disease (MASLD) has been found to be at alarming increase in Indian population. Prevalence of metabolic syndrome including Type 2 Diabetes Mellitus is also increasing which may be attributed to certain lifestyle changes. In the present study, we compared the likelihood of liver fibrosis by measurement of non-invasive scores among Type 2 diabetics and smokers, Type 2 diabetics but non-smokers and healthy controls. Our study will provide useful insights to evaluate the association between Type 2 diabetes, smoking and development of MASLD.
Methods: The study was done at a tertiary care hospital. Participants were divided into 3 groups (each of 40 participants) which included those with type 2 diabetes mellitus and smokers, those with type 2 diabetes mellitus but non-smokers and healthy controls. Parameters included in the database were age, sex, body mass index, history of diabetes, history of hypertension, any medication, tobacco use and alcohol consumption. Venous blood samples were taken in the morning after a 12-h overnight fasting and investigations were done. Results were recorded.
Results: FIB-4 score and AST/ALT ratio was significantly higher in diabetics and smoker patients, in comparison to diabetics but non-smokers and healthy controls.
Conclusions: Smoking and underlying type 2 diabetes mellitus have a synergistic effect on the severity of fibrosis, as compared to nonsmokers with type 2 diabetes mellitus. Hence smoking cessation, in addition to glycemic control with regular medication, may be beneficial in reducing the severity of MASLD among patients with type 2 diabetes mellitus.
References
Shalimar A, Bansal B, Gupta H. Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis. J Clin Exp Hepatol. 2022;12(3):818-29.
Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-85.
Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: Where do diabetologists stand. Clin Diabetes Endocrinol. 2020; 6:9.
Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus Mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599-612.
Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients. 2017;9: E387.
Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020; 2020:3920196.
Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54: 753-9.
Ou H, Fu Y, Liao W, Zheng C, Wu X. Association between smoking and liver fibrosis among patients with nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2019;2019:e6028952.
Charatcharoenwitthaya P, Karaketklang K, Aekplakorn W. Cigarette smoking increased risk of overall mortality in patients with nonalcoholic fatty liver disease: A nationwide population-based cohort study. Front Med. 2020;7:23-9.
Chavez-Tapia NC, Lizardi-Cervera J, Perez-Bautista O, Ramos OMH, Uribe M. Smoking is not associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2006;12: 5196-200.
Shen H, Peng JL, Tayarachakul S, Liangpunsakul S. Association between serum cotinine level and prevalence of non-alcoholic fatty liver disease: A cross-sectional study from the Third National Health and Nutrition Examination Survey. J Investig Med Am Fed Clin Res. 2017;65:43-8.
Marti-Aguado D, Clemente-Sanchez A, Bataller R. Cigarette smoking and liver diseases. J Hepatol. 2022; 77:191-205.
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. USA: Wiley; 2006.
Diabetes Standards of Care: ADA guidelines (2018), Available at: http://diabetesed.net/wp-content/ uploads/2017/12/2018-ADA-Standards-of-Care.pdf. Accessed on 22 April 2020.
Kawamoto R, Tabara Y, Kohara K, Miki T, Ohtsuka N, Kusunoki T, et al. Smoking status is associated with serum high molecular adiponectin levels in community-dwelling Japanese men. J Atheroscler Thromb. 2010;17:423-30.
Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Use of the FIB4 Index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol Clin Pract J Am Gastroenterol Assoc. 2009;7:1104-12.
Rutledge SM, Asgharpour A. Smoking and liver disease. Gastroenterol Hepatol. 2020;16:617-25.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
Yilmaz Y, Yonal O, Kurt R, Bavrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepatol Mon. 2011;11(2):103-6.
Jain P, Sharda M, Bauddh NK, Ajmera D. APRI score: A screening marker of hepatic fibrosis in NAFLD patients. J Assoc Physicians India. 2020;68: 97.
Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity. 2021;29: 1950-60.
Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, et al. Impact of Type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020; 26:444-53.
Artese A, Stamford BA, Moffatt RJ. Cigarette smoking: An accessory to the development of insulin resistance. Am J Lifestyle Med. 2017;13:602-5.
Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N, et al. Cigarette smoking and fat distribution in 21, 828 British men and women: A population-based study. Obes Res. 2005;13:1466-75.
El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol. 2006;12:6098-101.
Chalasani, Naga, Deeg, Mark A, Crabb, David W. Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis. Am J Gastroenterol. 2004;99(8):1497-502.
